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Several protein-bound uremic retention solutes (including
p-cresol) originate from colonic bacterial fermentation of
protein. Higher colonic availability of carbohydrates drives
this process towards lower production of toxic metabolites.
Small intestinal a-glucosidase inhibitors like Acarbose
(Glucobays) enhance the amount of undigested
carbohydrates reaching the colon. We studied the effect
of Acarbose on generation and serum concentrations of
p-cresol. Nine healthy volunteers (age 25 (22–36) years) with
a creatinine clearance of 89.6 ml/min/1.73 m2 (85.5–116.4)
were treated with Acarbose for 3 weeks. Dose was gradually
increased to reach 300 mg/day after 1 week. Blood sampling,
24-h urine and stool collections on 3 consecutive days were
performed before and during the last days of the treatment
period. p-Cresol generation was estimated from mean 24-h
urinary elimination. Gastrointestinal side effects, if present,
were mild to moderate. Serum concentrations of p-cresol
declined significantly after Acarbose treatment (before:
1.14 mg/l (0.93–3.03); after: 1.11 mg/l (0.31–1.82); P¼ 0.047).
Urinary excretion of p-cresol, reflecting its colonic generation
rate, was significantly lower after treatment (before:
29.93 mg/day (6.79–75.19); after: 10.54 mg/day (1.08–30.85);
P¼ 0.031). The fecal excretion of nitrogen increased after
treatment (before: 1.04 g/day (0.47–2.29); after: 1.99 g/day
(0.76–3.08); P¼ 0.047). This pilot study suggests that
Acarbose treatment lowers generation and serum
concentrations of the protein-bound uremic solute p-cresol.
Although further confirmation is warranted, the data may
point to a novel treatment option for chronic kidney disease
patients in view of the potential toxic effects of p-cresol and
related substances.
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The clinical syndrome of advanced renal insufficiency is
characterized by alterations of several biochemical and
physiological functions.1 Although the exact pathogenetic
mechanisms underlying these changes are not completely
understood today, it is generally accepted that the progressive
retention of a large number of compounds, which under
normal conditions are excreted by the healthy kidneys, plays a
central role. These so-called uremic retention solutes
comprise numerous substances that differ in water solubility,
protein binding, molecular mass, and dimensions.2 Much
research work has been dedicated to the study of small water-
soluble solutes and middle molecules. During the last
decades, however, another group of solutes has drawn the
attention of the nephrology community: protein-bound
solutes. Numerous in vitro findings suggest a role for
representatives of this class of molecules in the pathophysiol-
ogy of uremia.3–8 Moreover, recent clinical reports point to
the importance of these solutes in an in vivo situation.9–11
The landmark hemodialysis (HEMO) and adequacy of
dialysis Mexico (ADEMEX) studies failed to show an
improvement of patient outcome by increasing the removal
of small water-soluble solutes and even middle molecules
above current standards.12,13 Besides several other hypotheses
that have been put forward to explain these findings,14,15 one
should consider the limited removal of protein-bound solutes
by the dialysis strategies evaluated in these studies. Indeed,
the removal of protein-bound solutes during low- and high-
flux hemodialysis and peritoneal dialysis was shown to be
much lower than that of their water-soluble counterparts.11,16
In view of the above-mentioned data, there seems to be an
incentive to search for strategies that limit the accumulation
of protein-bound uremic retention solutes in patients with
renal insufficiency. Besides the exploration of alternative
dialysis modalities to improve their removal (e.g. daily
dialysis, hemodiafiltration, adsorptive strategies17–19), an-
other approach would be to interfere with the generation of
the molecules. In this regard, it is of note that several well-
known representatives of the protein-bound solutes (e.g.
p-cresol, indoxyl sulfate, and phenylacetic acid) originate
almost exclusively from bacterial protein fermentation in the
colonic lumen.20 Nutrient availability and especially the ratio
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of available carbohydrates to nitrogen have been reported to
be important factors influencing the fermentation process.
Some studies indicate a beneficial effect of dietary intake of
fermentable carbohydrates on fecal and urinary concentra-
tions of bacterial metabolites of amino acids.20,21 Indeed,
higher colonic availability of carbohydrates was shown to
drive the fermentation process towards lower production of
amino-acid metabolites through three different mechanisms.
First, fermentation of carbohydrate results in a decrease of
the pH through production of short-chain fatty acids. As
large intestinal proteases have a neutral to alkaline pH
optimum, protease activity will decrease resulting in a lower
availability of amino acids.22,23 Second, bacterial amino-acid
metabolism is decreased when fermentable carbohydrates are
present through the so-called ‘catabolite repression’.23,24 This
implies that in the presence of fermentable carbohydrates, the
expression of genes involved in bacterial metabolism of
amino acids is suppressed. Finally, fermentation of carbo-
hydrates provides an energy source to the microflora, thereby
expanding bacterial mass and increasing the incorporation of
ammonia and amino-acid nitrogen into the bacteria.25,26 The
oral hypoglycemic agent Acarbose (Glucobays) is an
inhibitor of the a-glucosidase enzymes in the brush-border
cells lining the small intestine and, as such, blocks the
hydrolysis of poly- and oligosaccharides to glucose and
other monosaccharides.27 As a result, non-digested poly-
and oligosaccharides enter the colonic lumen, where they
act as fermentable carbohydrates.28,29 The present pilot study
in healthy volunteers was conducted to test the hypothesis
that Acarbose treatment lowers the generation and serum
concentrations of the protein-bound uremic retention
solute p-cresol.
RESULTS
Daily generation and serum concentrations of p-cresol
Figure 1 shows individual data on serum concentrations and
urinary elimination of p-cresol. Descriptive and comparative
statistics for both intention-to-treat and per-protocol ana-
lyses are summarized in Table 1. In the per-protocol analysis,
serum p-cresol declined significantly after Acarbose treatment
as compared to the baseline period (full lines in the figure).
Also urinary excretion of p-cresol, as such or expressed per
gram of urea nitrogen as a correction for dietary protein
intake, declined significantly. In the subject receiving
antibiotic treatment and oral freeze-dried yeast, serum and
urinary p-cresol decreased (open squares), whereas there was
an increase in the participant who took iron supplements
(open triangles). Significance was lost when all participants
were considered together in the intention-to-treat analysis
(two-sided P-value for serum p-cresol levels¼ 0.098).
Fecal analysis
In Table 2, the results of the stool analyses are given. Median
fecal wet and dry weight and total daily fecal nitrogen
excretion were higher after treatment with Acarbose as
compared to the baseline period. However, the two-sided
Wilcoxon signed rank statistic was significant only for the
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Figure 1 | Serum concentrations and urinary output of p-cresol at
baseline and after 3 weeks of Acarbose treatment. Individual data
are illustrated. There were three protocol violators: (open squares)
one of them received antibiotic treatment and oral freeze-dried yeast,
(open triangles) one commenced oral iron supplements from the
second week, and (open circles) one reported having collected her
urines incompletely at baseline. As a consequence, the measured
baseline elimination of p-cresol in the latter subject is an under-
estimation of the real value. (Dashed lines: these data, considered to
be confounded by violations of the study protocol, were excluded
from the per-protocol analysis.)
Table 1 | p-Cresol serum concentrations and generation rate
Baseline Acarbose P-value
Intention-to-treat analysis
Serum p-cresol (mg/l) (n=9) 1.14 (0.93–3.03) 1.11 (0.31–1.93) 0.098
Serum urea nitrogen (mg/dl) (n=9) 22.7 (17.0–35.0) 21.7 (16.7–31.3) 0.496
Urinary p-cresol (mg/day) (n=9) 21.90 (6.79–75.19) 18.29 (1.08–49.02) 0.203
Urinary urea nitrogen (g/day) (n=9) 16.64 (9.23–32.18) 14.85 (9.95–23.6) 0.496
Urinary p-cresol/urea nitrogen ratio (mg/g) (n=9) 1.74 (0.46–6.33) 1.05 (0.05–3.81) 0.652
Per-protocol analysis
Serum p-cresol (mg/l) (n=7) 1.14 (0.93–3.03) 1.11 (0.31–1.82) 0.047
Serum urea nitrogen (mg/dl) (n=7) 24.0 (18.7–35.0) 25.3 (17.3–31.3) 0.578
Urinary p-cresol (mg/day) (n=6) 29.93 (6.79–75.19) 10.54 (1.08–30.85) 0.031
Urinary urea nitrogen (g/day) (n=6) 16.85 (13.13–32.18) 15.73 (9.95–23.60) 0.312
Urinary p-cresol/urea nitrogen ratio (mg/g) (n=6) 1.65 (0.46–6.33) 0.62 (0.05–2.38) 0.031
Data are expressed as median (minimum–maximum). Differences between baseline and acarbose treatment were evaluated by Wilcoxon signed rank test for paired data.
Two-sided P-values are indicated in the last column.
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increase of total daily fecal nitrogen excretion in the per-
protocol analysis. The amount of nitrogen per gram of
bacterial dry matter showed no change. In Figure 2, the
individual data on total fecal nitrogen excretion are
illustrated. In the subject receiving antibiotic treatment and
oral freeze-dried yeast, total fecal nitrogen excretion increased
(open squares), whereas there was a decrease in the
participant who took iron supplements (open triangles).
Dietary data, gastrointestinal side effects, and appetite
Based on the 7-day dietary records, no differences in dietary
intake of protein, carbohydrate, total energy, or dietary fiber
were noted between baseline and Acarbose treatment periods
(Table 3). Although nausea and vomiting were absent, most
subjects reported mild to moderate bloating and flatulence
during the treatment period. Acarbose induced lower
consistency of stools in all participants. The frequency of
stools showed only a moderate increase (from 9 (7–19) times
during the baseline week to a maximum of 14 (3–27) times
during the second treatment week (n¼ 9)). Figure 3
illustrates the individual data on bloating, flatulence, and
the consistency of stools. No relevant changes in appetite by
treatment with Acarbose were noted.
DISCUSSION
The results of this pilot study in healthy volunteers suggest
that treatment with Acarbose (Glucobays) diminishes the
colonic generation of p-cresol and results in a decline of its
serum concentrations (Table 1, Figure 1). Acarbose belongs
to a group of inhibitors of the small intestinal a-glucosidase
brush-border enzymes that were developed as an adjunct
therapy for the management of diabetes mellitus.30–32 It
blocks the hydrolysis of ingested poly- and oligosaccharides
to glucose and other monosaccharides. As a consequence,
glucose absorption is delayed and the post-prandial increase
in blood glucose is attenuated.27 As a result of this
mechanism of action, Acarbose causes more undigested
poly- and oligosaccharides to enter the large intestine.28,29 In
the present study, this side effect of the drug was exploited
with regard to its influence on bacterial protein fermentation
in the colon. Carefully designed in vitro studies showed that
higher colonic availability of carbohydrates diminishes
bacterial amino-acid fermentation through its pH-lowering
effect, its action as a bacterial energy source, and the process
of ‘catabolite repression’.22–26 Several lines of evidence
indicate that these mechanisms are most probably respon-
sible for the reduced colonic generation of p-cresol, a 108 Da
bacterial metabolite of the amino-acid tyrosine, and the
decrease of its serum concentrations as seen in the present
study. First, treatment with Acarbose was shown earlier to
enhance the colonic production of the short-chain fatty acid
butyrate with subsequent lowering of the intraluminal
pH.33–35 Second, in the present study there was a tendency
Table 2 | Fecal analyses
Baseline Acarbose P-value
Intention-to-treat analysis
Fecal weight (g/day) (n=9) 89.0 (46.3–274.7) 170.0 (29.0–276.7) 0.129
Fecal dry weight (g/day) (n=9) 19.4 (10.5–54.4) 33.2 (4.7–62.6) 0.164
Fecal dry weight (% of total) (n=9) 24.0 (11.3–31.3) 22.6 (16.3–39.7) 0.945
Fecal nitrogen (g/day) (n=9) 1.04 (0.47–2.29) 1.79 (0.32–3.08) 0.301
Fecal bacterial nitrogen (mg/g dry bacterial matter) (n=9) 57.4 (38.4–69.8) 55.1 (38.7–63.5) 0.496
Per-protocol analysis
Fecal weight (g/day) (n=7) 89.0 (46.3–274.7) 171.7 (34.0–276.7) 0.078
Fecal dry weight (g/day) (n=7) 19.4 (10.5–54.4) 37.4 (13.5–62.6) 0.078
Fecal dry weight (% of total) (n=7) 23.1 (11.3–31.3) 22.7 (20.7–39.7) 0.438
Fecal nitrogen (g/day) (n=7) 1.04 (0.47–2.29) 1.99 (0.76–3.08) 0.047
Fecal bacterial nitrogen (mg/g dry bacterial matter) (n=7) 57.4 (38.4–69.8) 55.1 (38.7–63.5) 0.578
Data are expressed as median (minimum–maximum). Differences between baseline and acarbose treatment were evaluated by Wilcoxon signed rank test for paired data.
Two-sided P-values are indicated in the last column.
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Figure 2 | Daily fecal total nitrogen excretion at baseline and
after 3 weeks of Acarbose treatment. Individual data are illustrated.
There were three protocol violators: (open squares) one of them
received antibiotic treatment and oral freeze-dried yeast, (open
triangles) one commenced oral iron supplements from the second
week, and (open circles) one reported having collected her urines
incompletely at baseline. The latter collection error will however not
have influenced the fecal measurements. (Dashed lines: these data,
considered to be confounded by violations of the study protocol,
were excluded from the per-protocol analysis.)
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for higher fecal nitrogen content after Acarbose treatment
(Table 2, Figure 2). This finding suggests inhibition of
deamination and/or increased use of ammonia by bacterial
anabolism.
Besides changes of the bacterial amino-acid metabolism
secondary to Acarbose treatment, also changes in dietary
intake of protein, carbohydrates, and fibers, or alterations of
colonic transit time may theoretically be responsible for the
declining p-cresol generation and serum concentrations.
Detailed study of these possible confounders was beyond
the scope of the present pilot study and will be further
investigated. However, we are convinced that the effects seen
in the present study are not induced by dietary changes, as
the findings were the same after correction for dietary protein
intake and no differences in macronutrient intake between
baseline and treatment period were noted based on a 7-day
dietary record (Table 3).
The results of the present pilot study are of course
preliminary and limited by the lack of statistical power. As
compared to the per-protocol analysis, statistical significance
was indeed lost in an intention-to-treat evaluation, which
included the subjects who violated the study protocol.
Although this may be reasonably explained by the influence
of the intercurrent medication taken by these subjects on
colonic fermentation and transit time,36–38 it is obvious that
our results should be confirmed by larger trials with longer
treatment periods. Nevertheless, the data of the present study
are of interest as they may provide a rationale for Acarbose
treatment in chronic kidney disease patients. This patient
population is exposed to particularly high concentrations of
p-cresol (20.10 (0.30–64.45) mg/l) in a group of 107
hemodialysis patients) and related protein fermentation
metabolites.2 Lowering the serum concentrations of these
solutes might be favorable in view of several toxic effects
attributed to them. Several in vitro studies point to a role of
p-cresol in immunodeficiency and endothelial dysfunction,
two important features of the uremic syndrome.3–6,39 We and
others have recently found, however, that p-cresol in human
body fluids is almost entirely present as its conjugated
metabolite p-cresylsulfate. The fact that p-cresylsulfate is
detected as p-cresol is owing to the deconjugating effect of
the analytical methodology used.40,41 Although the latter
findings may ask for a critical reappraisal of the in vitro
toxicity data on p-cresol (and of semantics in scientific
literature), they do not abrogate recently published clinical
associations between serum levels of this molecule and
Table 3 | Dietary data
Baseline Acarbose P-value
Intention-to-treat analysis
Protein intake (g/kg/day) (n=9) 0.95 (0.46–1.53) 1.00 (0.82–1.28) 0.652
Carbohydrate intake (g/kg/day) (n=9) 3.28 (2.16–7.02) 3.42 (2.15–4.15) 0.652
Energy intake (kcal/kg/day) (n=9) 30.5 (16.6–46.8) 29.1 (19.8–37.6) 1.000
Dietary fiber (g/day) (n=9) 15.0 (10.1–29.7) 15.2 (10.2–28.4) 0.301
Per-protocol analysis
Protein intake (g/kg/day) (n=7) 0.95 (0.46–1.53) 0.99 (0.83–1.28) 0.469
Carbohydrate intake (g/kg/day) (n=7) 3.28 (2.16–7.02) 3.42 (2.15–4.15) 1.000
Energy intake (kcal/kg/day) (n=7) 30.5 (16.6–46.8) 31.4 (19.8–37.6) 0.813
Dietary fiber (g/day) (n=7) 20.3 (12.7–29.7) 15.9 (10.2–28.4) 0.219
Data are expressed as median (minimum–maximum). Differences between baseline and acarbose treatment were evaluated by Wilcoxon signed rank test for paired data.
Two-sided P-values are indicated in the last column.
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Figure 3 | Bloating, flatulence, and consistency of stools at
baseline and during Acarbose treatment. Individual data are
illustrated. For display purposes, the day scores (0, 1, or 2 for
‘bloating’ and ‘flatulence’; 0, 1, or 2 for ‘consistency of stools’)
were added up per week of the study (baseline week; treatment
weeks 1, 2, and 3). There were three protocol violators: (open
squares) one of them received antibiotic treatment and oral freeze-
dried yeast, (open triangles) one commenced oral iron supplements
from the second week, and (open circles) one reported having
collected her urines incompletely at baseline. The latter collection
error will, however, not have influenced the symptom scores.
(Dashed lines: these data, considered to be confounded by violations
of the study protocol, were excluded from the per-protocol analysis.)
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features of uremia. Indeed, in a study by De Smet et al.,10 free
serum levels of the solute were shown to be greater in
hemodialysis patients hospitalized for infectious disease.
Furthermore, a positive relationship was found between
serum total p-cresol levels and a uremic symptom score in
patients treated with peritoneal dialysis, whereas a correlation
with small water-soluble solutes and the middle molecule
b2-microglobulin was absent.
11 Even more striking, however,
are the findings of a prospective observational study in
patients treated with conventional hemodialysis (3 4 h/
week), indicating that the accumulation of p-cresol is a risk
factor for overall mortality.42 Indoxyl sulfate – a bacterial
metabolite of tryptophane – was found to inhibit endothelial
proliferation and wound repair.6 Moreover, the molecule was
shown to induce free radical production by renal tubular cells
and to activate NF-kB, a central mediator of atherosclerosis.7
Earlier studies by Niwa et al.9 showed that the molecule
constitutes one of the factors responsible for the progression
of glomerular sclerosis in rats and humans. Recently, another
protein-bound solute and bacterial metabolite of phenylala-
nine, phenylacetic acid, was identified to have an inhibitory
impact on inducible nitric oxide synthase, an enzyme with a
protective potential on endothelial function.8 Also several
polyamines (some of which are protein-bound) originate
from bacterial amino-acid fermentation. These molecules
have been shown to be related to the accelerated athero-
sclerosis of renal disease.43,44 Moreover, some of them are
implicated in renal anemia.45,46
Besides its effect on the serum concentrations of toxic
amino-acid metabolites, treatment with Acarbose may have
some additional benefits. Through its positive influence on
the post-prandial glucose and insulin levels, Acarbose
treatment can be expected to ameliorate the serum lipid
profile.47,48 This may be of interest in view of the high
cardiovascular risk of renal patients and of the possible
implications of lipid abnormalities in the progression of renal
disease.49 Furthermore, by increasing the amount of
undigested carbohydrates reaching the large intestine,
Acarbose mimics the effects of prebiotics. The latter are
known for their protective role in carcinogenesis, their
neutralizing influence on intestinal pathogens and, again,
their beneficial effect on lipid profiles.50
As expected, most of the participants in the present study
reported gastrointestinal side effects of the Acarbose treat-
ment (Figure 3).51 None of the subjects, however, scored
them as ‘severe’. In contrast to other a-glucosidase inhibitors,
Acarbose is not absorbed from the intestinal lumen,
indicating that it may be safe in patients with renal
insufficiency.32,52 Specific data on side effects and safety of
Acarbose in this particular patient population, however, are
lacking to date and further investigation will be needed
before it can be clinically used.
Finally, it is worth mentioning that apart from the use of
Acarbose, several other interventions at the intestinal level
have been described in order to reduce the generation of
p-cresol and related substances. The oral adsorbent AST-120,
for instance, resulted in lower serum levels of p-cresol in a
uremic rat model.53 An oral preparation of lactic acid
bacteria reduced the amount of fecal p-cresol in a group of
hemodialysis patients, studied by Hida et al.54 Like our
present data, the results of each of these studies are
supportive for a role of protein fermentation in uremia.
In conclusion, the results of this pilot study suggest that
Acarbose treatment lowers generation and serum concentra-
tions of the protein-bound uremic solute p-cresol. Although
further confirmation is warranted, the data may point to a novel
treatment option for chronic kidney disease patients in view of
the potential toxic effects of p-cresol and related substances.
MATERIALS AND METHODS
Study design
We performed a pilot study in healthy volunteers. After a 1 week
baseline period, subjects were treated with Acarbose (Glucobays)
for 3 weeks. Dose was gradually increased to reach 300 mg/day at the
end of the first treatment week (3 days: 3 50 mg/day; 3 days
2 100 mg/day; from the 7th day: 3 100 mg/day). Fasting blood
samples were taken and 24-h urine and stool collections were
performed on 3 consecutive days at the end of the baseline period
and during the last 3 days of the treatment period. Urine collection
bottles were refrigerated (0–41C) and stool vials were frozen
(201C) at the participant’s home to prevent bacterial growth and
brought to the laboratory daily within hours of the time that the
collection ended. Urine collections were vigorously stirred, weighed,
and sampled. Serum and urine samples were stored at 801C and
stool collections at 201C until analysis. Subjects were asked to
perform a 7-day dietary record during the baseline week and the last
week of the treatment period. Finally, gastrointestinal side effects
and appetite were evaluated daily throughout the study.
Study end points
The primary end point of the study was the effect of Acarbose
treatment on daily generation and serum concentrations of p-cresol.
Secondary end points comprised changes in fecal parameters,
dietary intake of protein, carbohydrate, energy and fiber, and clinical
side-effects.
Study population
Nine healthy volunteers (three men, age 25 (22–36) years)
participated in the study. None of them was known with renal
disease or impaired renal function. Creatinine clearance, estimated
by the Cockcroft and Gault formula, was 89.6 (85.5–116.4) ml/min/
1.73 m2. No actual or former metabolic, cardiovascular, gastro-
intestinal, or respiratory disease was present. None of the
participants had used drugs known to influence gastrointestinal
motility (prokinetics or antiemetics), protein assimilation, or
fermentation (prebiotics, probiotics, antibiotics, or inhibitors of
gastric acid secretion) during the preceding 3 months. Except for
Acarbose, no other drug changes were allowed. The subjects were
asked to keep their usual dietary habits throughout the study period.
The study was approved by the ethical committee of the University
Hospital Gasthuisberg and written informed consent was obtained
from all participants.
Daily generation and serum concentration of p-cresol
In a steady-state situation, total daily elimination of a molecule
equals its daily generation. Because most of the p-cresol produced in
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the colon is absorbed by the mucosa, urinary output of the molecule
reflects its generation.11,55,56 In the present study, daily generation of
p-cresol at baseline and after Acarbose treatment was estimated from
the 3-day mean of its urinary elimination, calculated on the basis of
measured p-cresol concentrations of frozen urine samples and
volumes. As a reflection of dietary protein intake, 24-h elimination
of urea nitrogen was calculated as well using the same approach.57
Three-day mean serum concentrations of urea nitrogen and total
p-cresol at baseline and after Acarbose treatment were calculated
from measurements on frozen samples.
Serum creatinine, serum urea nitrogen, and urinary urea
nitrogen concentrations were measured using standard laboratory
techniques. Serum and urinary total p-cresol concentrations were
determined by gas chromatography–mass spectrometry technology
as described earlier.11,18,40,55 In summary, after deproteinization
(acid and heat), addition of the internal standard (2,6-dimethyl-
phenol) and extraction (ethyl acetate), the samples were transferred
to the gas chromatography–mass spectrometry (trace gas chromato-
graphy–mass spectrometry; Thermofinnigan, San Jose´, CA, USA).
Quantitative results were obtained by the internal standard method
and calculated as concentrations (mg/l).
Fecal measurements
All stools collected during each 3-day period were combined and
weighed. After dilution with 1000 ml sterile pyrogen-free water and
homogenization, a sample of known weight was taken and freeze-
dried. The dried material was weighed again.
Separation of feces into bacterial and non-bacterial fractions was
performed according to Stephen and Cummings.58 An aliquot of
500 mg freeze-dried fecal material was thoroughly mixed for 10 min
with 30 ml of formylsaline (1% formaldehyde in 0.9% saline) and
0.30 ml of 10% sodium lauryl sulfate. The mixture was filtered
through a 20 mm filter (Varian Inc., Palo Alto, CA, USA) under
vacuum and the residue was washed with 30 ml of formylsaline,
shaken, and filtered again. This procedure was repeated twice
resulting in about 90 ml of filtrate. The filtrate was ultracentrifuged
at 25 000 g during 36 min. The supernatant, containing the water-
soluble compounds, was discarded, whereas the sediment, contain-
ing the bacteria, was dissolved in 2 ml sterile pyrogen-free water.
After weighing, the sediment was freeze-dried and the dried material
was weighed again.
Nitrogen content of total stools and bacterial fraction was
measured by continuous flow elemental analysis-isotope ratio mass
spectrometry (Automated Nitrogen Carbon Analyzer-New Techno-
logy Solid/Liquid Preparation Module 20–20 Stable Isotope Analyzer;
Europa Scientific, Crewe, United Kingdom). An aliquot of feces or
bacterial mass (freeze-dried, about 7 mg) is oxidized using copper
oxide, oxygen, and chromium oxide at 10001C. The resultant
nitrous oxides are then reduced to nitrogen gas using copper at
6001C, which is led to the ion source of the mass-spectrometer. Total
nitrogen content is measured based on the nitrogen peak areas with
reference to a calibrated laboratory standard (i.e. a standard
ammonium sulfate solution).
Based on the above analyses, the following parameters were
calculated: fecal weight (g/day), fecal dry weight (g/day or % of total
weight), fecal nitrogen (g/day), and fecal bacterial nitrogen (mg/g of
bacterial dry matter).
Dietary data, gastrointestinal side effects, and appetite
Dietary protein (g/kg/day), carbohydrate (g/kg/day), energy (kcal/
kg/day), and dietary fiber intake (g/day) at baseline and during
Acarbose treatment were evaluated by computer calculations based
on the 7-day dietary records.
Subjects were asked to grade the intensity (0, absent; 1, mild; 2,
moderate; 3, severe and interfering with daily activities) of the
following gastrointestinal side effects of Acarbose on a daily basis
during the entire study period: nausea, vomiting, bloating, and
flatulence. Furthermore, they were asked to note the frequency
(times per day) and the consistency (0, normal; 1, loose; and 2,
diarrhea) of stools. Appetite was evaluated as increased, decreased,
or unaltered as compared to normal circumstances. For display
purposes, the day scores were added up per study week (baseline
week; treatment weeks 1, 2, and 3).
Data analysis and statistics
All nine participants completed the entire study period. In two
subjects, however, protocol violations were noted. One female
received antibiotic treatment (Furadantines) for a suspected
urinary tract infection during the Acarbose treatment period. In
addition, she started oral treatment with a freeze-dried yeast
(Saccharomyces boulardii; Perenterols) owing to diarrhea during the
third treatment week. Another female subject commenced oral iron
supplements (ferro-gluconate; Losferrons) from the second week of
treatment. These intercurrent therapy changes might have influ-
enced the production of bacterial protein metabolites through
changes in microflora or gastrointestinal motility. A third female
participant reported having collected her urines incompletely at the
beginning of the study. As a consequence, the measured baseline
elimination of p-cresol is an underestimation of the real value.
In an intention-to-treat analysis, the data of all nine subjects
were evaluated. To account for the study violations mentioned
above, a per-protocol analysis was performed with exclusion of the
two subjects who received intercurrent therapies. In addition, the
urinary data of the participant who reported urinary collection
errors were excluded from this per-protocol analysis.
Data are expressed as median (minimum–maximum). For both
intention-to-treat and per-protocol analyses differences between
baseline and Acarbose treatment data were evaluated using the
Wilcoxon signed rank test. In the figures, individual data are shown
(dashed lines for data considered to be confounded by violations of
the study protocol). P-valueso0.05 were considered significant. The
SAS version 8.02 (SAS Institute, Cary, NC, USA) software program
was used for the statistical analysis.
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